Bone Graft Substitutes – Market Insights – Global

Long-term growth in the global BGS market will be driven by the uptake of novel technologies, the expanding indication approvals, site-of-service flexibility, and strategic mergers and acquisitions among companies offering complementary solutions. However, bulk purchasing by hospitals will drive ASPs down, hindering market growth.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for BGS in the US, Europe, Asia Pacific, and Latin America from 2019 through 2035.

BGS products face varying levels of regulatory restrictions, significantly impacting product approvals and adoption.

How will companies use the regulatory landscape to their advantage in the US market?

How do regional regulatory frameworks shape the competitive dynamic within a given region?

Clinical data is limited for BGS products, leading to advantages for manufacturers that can demonstrate clinical efficacy.

Which products and brands are undergoing trials to solidify their value proposition and increase adoption?

How do reimbursement patterns resulting from updated clinical data affect market dynamics?

BGS used in spinal fusion procedures will see strong growth over the forecast period.

What is driving strong growth in this segment?

What will shift the growth trend in the spinal fusion procedures?

In the Asia Pacific and Latin American BGS markets, domestic manufacturers have gained significant market share.

What actions can MNCs take to remain competitive in Asia Pacific or Latin American countries?

What product types are local manufacturers specializing in, and what gap does that leave for competitors that want to enter the market?

Manufacturers are increasingly leveraging distribution partnerships to develop and market BGS products.

Which companies have entered into partnerships?

Which types of partnerships exist, and what benefit have they had in the market so far?